根据先前的研究表明indicating基团和唑环对血小板的抗凝活性具有药理作用,合成了一系列结构中同时具有hydr和唑(咪唑)环的化合物,并评估了它们对血小板凝集的抑制作用。这些1-(亚芳基氨基)-4-芳基-1H-咪唑-2-胺衍生物中的两种,化合物4a [((E)-1-(苄叉基氨基)-4-苯基-1H-咪唑-2-胺]和4 p [(E)-4-苯基-1-((噻吩-2-基亚甲基)氨基)-1H-咪唑-2-胺]的IC50值类似于乙酰水杨酸作为胶原蛋白的血小板聚集诱导剂。
2-Amino-1-arylidenaminoimidazoles, a novel class of orally (po) active microtubule-destabilizing anticancer agents, were synthesized. The compounds were designed from a hit compound identified in a drug discovery platform by using cancer cell-based high throughput screening, assay. Selective synthesized compounds exerted cell cytotoxicity against human cancer cells. The underlying mechanisms for the anticancer activity were demonstrated as interacting with the tubulins and inhibiting, microtubule assembly, leading to proliferation inhibition and apoptosis induction in the human tumor cells. Furthermore, two compounds showed in vivo anticancer activities in both po and intravenously (iv) administered routes and prolonged the life spans of murine leukemic P388 cells-inoculated mice. These new po active anti mitotic anticancer agents are to be further examined in preclinical studies and developed for clinical uses.